BPIFA3

Across TCGA pan-cancer cohorts, BPIFA3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BPIFA3 data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BPIFA3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BPIFA3 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

UCEC, LIHC, and SKCM are the cancer types where BPIFA3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	0.196	0.556	.035	6	view →
SKCM	OS	Median	II,III,IV	0.215	0.731	.001	3	view →
COAD	DFS	Median	All	1.000	0.506	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BPIFA3–UCEC (OS)

Open the UCEC breakdown →